The adenovirus type 5 gene E1A is known to suppress tumorigenicity by transcriptionally downregulating HER-2/neu (HER2) or by inducing apoptosis. We show here that E1A also suppressed the tumorigenicity of the low-HER2-expressing ovarian cancer cell line OVCAR-3 by decreasing cell proliferation. We further found that the mechanism responsible for this reduced proliferation is the presence of PEA15 (phosphoprotein enriched in astrocytes), which is upregulated by E1A in ovarian cancer; PEA15 promotes translocation of ERK from the nucleus to the cytoplasm, leading to inhibition of ERK-dependent transcription and proliferation. Indeed, siRNA-mediated knockdown of PEA15 expression in OVCAR-3 stable E1A transfectants resulted in a nuclear accumulation of the active form of ERK, followed by an increase in Elk-1 activity, DNA synthesis, and anchorage-independent growth. Finally, PEA15 by itself suppressed colony formation in breast and ovarian cancer cell lines, in which E1A is known to have antitumor activity. We conclude that part of the antitumor effect of E1A in ovarian cancer results from cytoplasmic sequestration of the activated form of ERK by PEA15.
Introduction
Ovarian cancer is a major cause of death among women in the United States. In 2004, 25 580 new cases are expected to be diagnosed and 16 090 women will die of the disease, accounting for 6% of all cancer deaths in women (Jemal et al., 2004) . Understanding the molecular mechanisms of tumor development and new antitumor therapies may enable us to identify more effective treatments for ovarian cancer. Administration of the adenovirus type 5 gene E1A is one such treatment that is currently in development for clinical use Hortobagyi et al., 2001) . The product of the E1A gene, a well-known transcriptional regulator, inhibits the overexpression of HER2 in both ovarian and breast cancer cells (Yu et al., 1990 (Yu et al., , 1993 Chang et al., 1997; Zang et al., 2001) . Downregulation of HER2 overexpression by E1A suppressed the tumorigenicity of the HER2-overexpressing human ovarian cancer cell line SKOV3.ip1 (Yu et al., 1993) , but tumors induced in female nu/nu mice by the low-HER2-expressing ovarian cancer cell line 2774 did not respond to treatment with adenoviral E1A (Zhang et al., 1995) . Other investigators have found that E1A can inhibit tumorigenicity in other types of cancer regardless of HER2 expression, but not in ovarian cancer (Frisch and Dolter, 1995) .
A phase I clinical trial based on these findings was begun in 1995 at The University of Texas M. D. Anderson Cancer Center in which the E1A gene, complexed with cationic liposomes, was given by i.p. injection to patients with advanced or recurrent ovarian or breast cancer. Results of that trial showed that ovarian and breast cancer cells could be transfected with E1A given in this way, and that the transfected cells showed downregulation of HER2. However, we observed reduced proliferation and increased apoptosis not only in HER2-overexpressing cells but also in cells expressing low levels of HER2 (Hortobagyi et al., 2001 ). This observation is consistent with a previous report that E1A can inhibit tumorigenicity in other types of cancer cell lines regardless of their HER2 expression (Frisch and Dolter, 1995) . Therefore, E1A may have HER2-independent tumor-suppressive functions.
The antitumor effect of E1A can be explained by its induction of apoptosis, its blockade of invasion and metastasis, and its suppression of proliferation. E1A expression has been reported to induce apoptosis by both p53-dependent and p53-independent mechanisms (Teodoro et al., 1995) and by inhibition of NF-kB activation . E1A has also been shown to suppress metastasis via downregulation of metalloproteinase and E-cadherin expression, to increase cytolysis by cytotoxic T lymphocytes or natural killer cells via increased immunogenicity (Mymryk, 1996) , and to transcriptionally repress proteases important in metastasis such as type IV collagenase (Frisch et al., 1990; Yu et al., 1992) , plasminogen activator (Young et al., 1989) , interstitial collagenase, and urokinase (Frisch et al., 1990) . E1A also regulates differentiation in some types of cells such as embryonal carcinoma F9 cells (Nelson et al., 1990) and can confer an epithelial cell morphology upon tumor cells (Frisch, 1994) . However, the mechanisms by which E1A suppresses the proliferation of cancer cells have not been defined.
To identify the HER2-independent antitumor mechanisms of E1A, we searched for target genes affected by E1A expression in the low-HER2-expressing ovarian cancer cell line OVCAR-3. By comparing a DNA microarray of vector-control OVCAR-NP cells and E1A-overexpressing OVCAR-3 cells, we identified PEA15 (phospho-enriched protein in astrocytes), an acidic, serine-phosphorylated, 15-kDa phosphoprotein, as a potential target of E1A. PEA15 is highly expressed in the brain (astrocytes), eye, lung, thymus, adrenal gland, heart, kidney, spleen, and muscle (Danziger et al., 1995; Estelles et al., 1996) . Phosphoprotein enriched in diabetes (PED), a homolog of PEA15, is overexpressed and controls glucose transport in patients with type II diabetes (Condorelli et al., 1998) . PEA15 is also known to block ERK-dependent proliferation by binding to ERK and sequestering ERK in the cytoplasm (Formstecher et al., 2001) . This sequestration effect results in part from PEA15 interfering with ERK's ability to interact with nucleoporins, components of the nuclear pore complex (Whitehurst et al., 2004) . Activated ERK contributes to cell proliferation and anchorage-independent growth, which correlates with tumorigenicity (Freedman and Shin, 1974) . Antisense nucleotides to ERK and dominant-negative forms of ERK have been shown to inhibit proliferation in NIH3T3 fibroblasts (Pages et al., 1993) . Also, ERK1
-/-mice show a twofold reduction in the number of mature thymocytes (Pages et al., 1999) . Moreover, blocking the MAPK pathway inhibited tumor growth in mice harboring colon cancer and reduced the potential for metastasis in this model (Sebolt-Leopold et al., 1999) . Therefore, we sought here to determine if suppression of cell proliferationpresumably part of the antitumor activity of E1A -depends on the ability of PEA15 to inhibit the translocation of ERK to the nucleus.
Results
E1A inhibits the tumorigenicity of low-HER2-expressing ovarian cancer cells Samples obtained from a previous human clinical trial of E1A gene therapy showed reduced levels of (reflecting inhibition of cell proliferation) in cancer cells from E1A-treated patients regardless of the HER2 expression levels of those cells (Hortobagyi et al., 2001) . Thus, we first carried out an in vitro study of OVCAR-3 cells, previously shown to respond to transfection with Ad.E1A by suppression of tumorigenicity (manuscript in press, Cancer Research), to determine if Ad.E1A( þ ) could inhibit cell proliferation in vitro. We found that infecting OVCAR-3 cells with Ad.E1A( þ ) reduced their growth rate to 5.3% of that of cells expressing a mock vector at 96 h (Po0.05), and that this reduction correlated with an increase in cell death ( Figure 1a) .
We next generated OVCAR-3 cell lines that constitutively express E1A (Figure 1b) . We confirmed a reduction in DNA synthesis, another hallmark of reduced cell proliferation, in the OVCAR-E1A cells relative to that in the parental cells, as indicated by BrdU incorporation (Figure 1c ). We also tested their ability to form colonies in soft agar, an indicator of in vivo tumorigenicity. We found that the two OVCAR-E1A clones tested (OVCAR-E27 and OVCAR-E28) formed 64% fewer colonies in soft agar than did control cells (parental OVCAR-3 or OVCAR-NP cells) (Po0.001) (Figure 1d ).
PEA15 is upregulated in OVCAR-E1A cells and sequesters ERK in the cytoplasm
To identify targets of E1A that mediate its inhibitory effect on cell proliferation, we compared the gene expression profiles of the vector-control OVCAR-NP cells with those of the OVCAR-E1A cells. We initially identified many genes that were differentially expressed between the vector-control cells and the E1A-expressing cells. We then attempted to confirm the differential expression of those candidate genes in terms of their protein levels. Among the candidate gene products, PEA15 was found to be upregulated in the OVCAR-E1A transfectants as compared with control cells (OVCAR-3 or OVCAR-NP) by Western blot analysis (Figure 2a ). Immunofluorescence staining also showed that PEA15 protein was more highly expressed in the OVCAR-E1A cells than in the OVCAR-NP controls (Figure 2b ). PEA15 was also upregulated in the ovarian cancer cell line SKOV3.ip1 stably transfected with E1A (Supplementary Figure) . These findings suggest that E1A expression is involved in the upregulation of PEA15.
PEA15, a multifunctional protein that regulates both apoptosis and cell proliferation (Renault et al., 2003) , has been found to relocate ERK from the nucleus to the cytoplasm (Formstecher et al., 2001; Renault et al., 2003; Whitehurst et al., 2004) , leading to suppression of proliferation. We thus next assessed the location of ERK and phosphorylated (activated) ERK (pERK) in the E1A-expressing cells. Subcellular fractionation studies revealed that ERK and pERK were largely confined to the cytoplasm in the OVCAR-E1A transfectants relative to the vector control OVCAR-NP (Figure 2c) . Thus, high levels of PEA15 in OVCAR-E1A cells were associated with ERK and pERK being sequestered in the cytoplasm. Finally, to confirm this effect in another cell line that overexpresses E1A, we tested another ovarian cancer cell line (SKOV3-ip1 and SKOV3-ip1-E1A) and found that the fractionation data were similar, that is, pERK was located mostly in the cytoplasm in the SKOV3-ip1-E1A in contrast with the SKOV3-ip1 parental cells, where pERK was located in both the cytoplasm and the nucleus (data not shown). Further, we found no consistent trends in the extent of reduction of ERK 1/2 expression across E1A transfectants compared to the parental cells.
To examine if the location of pERK (nuclear or cytoplasmic) depends on PEA15, we next suppressed PEA15 expression by using siRNA. Transfection of OVCAR-E1A cells with siRNA specific for PEA15 sharply reduced the levels of PEA15 protein ( Figure 3a ) and led to accumulation of pERK in the nuclei of those cells ( Figure 3b ). In quantifying the proportion of cells with a nuclear pERK1/2 staining pattern, we found the number of cells with nuclear staining to be significantly increased after siPEA15 treatment (by 30%) as compared with siControl treatment (by 6%) (Po0.001, w 2 test). We also used the NIH Image program to quantify staining intensity on fluorescent images of siControltreated or siPEA15-treated cells; the ratio of nuclear intensity/total cell intensity (nuclear þ cytoplasm) ( Figure 3b ) was increased in the siPEA15-treated cells relative to that of siControl-treated cells (Po0.0001). To determine whether the nuclear location of ERK affected ERK activity, we measured the transcriptional activity of Elk, which is known to be activated by pERK. Elk activity was indeed low in the OVCAR-E1A cells relative to Elk activity in the control OVCAR-NP cells (Figure 3c ), and depletion of PEA15 by siRNA restored the Elk-1 activity in the OVCAR-E1A cells ( Figure 3d ). Collectively, these findings suggest that ERK activity is regulated by the presence of PEA15.
The antitumor effect of E1A in ovarian cancer cells depends on PEA15 We next determined whether the observed E1A-induced decrease in DNA synthesis in the OVCAR-E1A cells depends on the presence of PEA15. To do so, we transfected OVCAR-E1A cells with either siPEA15 or siControl, incubated them at 371C for 30 h and then with BrdU for another 20 h, and assessed BrdU incorporation by fluorescence-activated cell sorting (FACS) analysis. Indeed, the proportion of cells incorporating BrdU (i.e., proliferating) was higher in the OVCAR-E1A cells treated with siPEA15 (75%) than in siControl-treated cells (49%) or untreated cells (55%) (Figure 4a ).
We also examined whether depletion of PEA15 would facilitate anchorage-independent growth of the Equal amounts (50 mg) of cytoplasmic (C) and nuclear (N) fractions were analysed by PAGE on a 12% SDS gel. The blots were probed with antibodies to ERK1/2 (top row), pERK (second row), a-tubulin (third row), and PARP (bottom row) to verify separation of the cytosolic and nuclear fractions. Most of the ERK in the OVCAR-E1A cells accumulated in the cytoplasm rather than in the nucleus. Less ERK was expressed in the E1A-expressing cells than in the control cells.
OVCAR-E1A cells. The mean number of colonies formed by the siPEA15-treated E1A stable transfectants was three times as high as that of the siControl-treated cells (Po0.05) (Figure 4b ), suggesting that silencing PEA15 led to promotion of cell growth through increasing DNA synthesis and anchorage-independent growth. Hence in OVCAR-3 ovarian cancer cells, the antitumor activity of E1A depends on PEA15.
PEA15 inhibits human ovarian cancer cell growth in vitro Finally, to determine whether PEA15 itself could suppress tumorigenicity in vitro, we transfected three ovarian cancer (SKOV3.ip1, 2774-C10, and OVCAR-3) and two breast cancer (MDA-MB-435 and MDA-MB-231) cell lines with a vector control (pcDNA3) or with hemagglutinin (HA)-PEA15 (HA-PEA15 cloned into pcDNA3) and assessed cell growth and colony-forming ability. Fewer G418-resistant colonies were found in the PEA15 transfectants (relative to the vector controls) in the SKOV3.ip1, OVCAR-3, and MDA-MB-231 cell lines (Figure 5a ), suggesting that PEA15 has a growthinhibitory effect on these cells. As a final test of the putative link between PEA15 expression and suppression of tumorigenicity, we established stable SKO-V3.ip1-PEA15 transfectant cells and screened the G418-resistant colonies for PEA15 expression by Western blot analysis. Of the three clones obtained, ip1-P1 expressed the greatest amount of PEA15 protein ( Figure 5b ). Clones 1 and 2 both grew at slower rates than the parental cells, vector-control cells, or a third clone (which expressed little to no PEA15) (Figure 5c ), which could be related to the difference in PEA15 protein levels. This apparent growth-inhibitory effect of PEA15 was confirmed in an anchorage-independent growth assay, in which clones 1 and 2 produced fewer colonies than the vector control (Figure 5d ), but the low-PEA15-expressing clone 3 showed no reduction in number of colonies compared with the vector control.
In addition, the PEA15-expressing clone sequestered The nuclei were stained with DAPI (red). The pERK (green) in the siRNA control-treated cells was in both the nuclei and cytoplasm (top), but was mostly in the nuclei of the siPEA15-treated cells (bottom). The relative intensity of the fluorescence was quantified by using the NIH Image program and was calculated by measuring the ratio of nuclear intensity/total cell intensity (nuclear þ cytoplasm). (c) Elk-1 transcriptional activity was decreased in OVCAR-E1A cells. OVCAR-NP and OVCAR-E1A cells were transfected with pFR-luc (1 mg), pFA2-Elk-1 (50 ng), and pRL-TK (100 ng). Cells were lysed 48 h later and Elk-1 transcriptional activity was measured. (d) Knockdown of PEA15 expression by siRNA restored Elk-1 activity in OVCAR-E1A cells. Cells were transfected with siControl or siPEA15 and transfected again the next day with pFR-luc (1 mg), pFA2-Elk-1 (50 ng), and pRL-TK (100 ng), grown in reduced serum (0.5%) for 24 h, and then stimulated with medium containing 20% serum for 30 min, after which they were lysed and Elk-1 transcriptional activity measured.
E1A antitumor effect via PEA15 C Bartholomeusz et al pERK in the cytoplasm in response to serum stimulation, with a minimum amount of pERK in the nucleus. As expected, the increased expression of PEA15 resulted in impaired translocation of ERK into the nucleus (Figure 5e ). Collectively, these results demonstrate that PEA15 suppresses the growth of ovarian cancer in vitro.
Discussion
Our findings indicate that PEA15 was upregulated in E1A-expressing ovarian cancer cells and that PEA15 mediated the antitumor effect of E1A by preventing the nuclear localization of ERK and hence blocking ERKdependent transcription and proliferation. SKOV3.ip1 cells made to constitutively express E1A also revealed upregulation of PEA15 (data not shown). These results illustrate a novel additional mechanism underlying the antitumor activity of E1A, supplementing previously known mechanisms such as downregulation of HER2 (Yu et al., 1990; Yan et al., 1991) , inhibition of angiogenesis , and metastasis (Frisch et al., 1990; Yu et al., 1991 Yu et al., , 1992 Yu et al., , 1995 Mymryk, 1996) , suppression of transformation (Douglas et al., 1991; Frisch, 1991; Yu et al., 1991; Frisch and Dolter, 1995; Mymryk, 1996) , induction of differentiation (Nelson et al., 1990; Frisch, 1994) , induction of apoptosis (Rao et al., 1992; Debbas and White, 1993; Teodoro et al., 1995; Deng et al., 1998) , and downregulation of the Axl receptor (Lee et al., 1999) . Further studies are needed to establish the mechanism by which E1A upregulates PEA15 (e.g., upregulation of mRNA or stabilization of PEA15 protein). PEA15 binds to the mitogen-activated protein kinase ERK and blocks ERK-dependent cell proliferation by sequestering ERK in the cytoplasm, where it cannot activate target genes (Formstecher et al., 2001 ). Our observations support those of previous studies in which overexpression of PEA15 inhibited the proliferation of HEK293 cells (Condorelli et al., 2002) and in which increased PEA15 expression was linked to suppression of cell proliferation (Danziger et al., 1995; Formstecher et al., 2001) . However, none of these previous studies had linked PEA15 with suppression of tumorigenicity. Indeed, our results also indicate that PEA15 itself has antitumor activity, as reflected by its ability to suppress colony formation of breast cancer cells (MDA-MB-231) and ovarian cancer cells (OVCAR-3, SKOV3.ip1) -all cell lines in which E1A has proven antitumor activity.
PEA15 is a multifunctional protein that regulates both apoptosis and cell proliferation. Its role in apoptosis has been unclear, with studies reporting conflicting results. In one study of MCF-7 and HeLa cells, apoptosis induced by FasL and tumor necrosis factor (TNF) was inhibited when PED/PEA15 was overexpressed. This inhibition was due to PED binding to the receptor-FADD-FLICE signaling complex, which abrogates further activation of caspases (Condorelli et al., 1999) . However, another study described PEA15 as inhibiting FasL-induced apoptosis, but increasing TNF-R1-mediated caspase-8 activity and apoptosis. In that study, point mutations at one or both of two phosphorylation consensus sites within PEA15 (Ser 116 and Ser 104 ) destroyed its effect on Fas-mediated, but not TNF-R1-mediated, apoptosis (Estelles et al., 1999) . Another group found that Ser 116 is phosphorylated by calcium-calmodulin kinase II (Araujo et al., 1993) and Ser 104 by protein kinase C (Kubes et al., 1998) . Akt can also phosphorylate PEA15/PED at Ser 116 , which increases the stability and antiapoptotic function of PEA15/PED (Trencia et al., 2003) . Thus, the phosphorylation status of PEA15 seems to be important in its apoptotic function. In HEK293 cells, the unphosphorylated form was apoptotic, but the phosphorylated form was antiapoptotic (Trencia et al., 2003) . When PEA15 is phosphorylated at both Ser 104 and Ser 116 , it blocks its interaction with ERK 1/2 both in vitro and in vivo, resulting in proliferation of cells that express high levels of PEA15 (Krueger et al., 2005) . In another report, it has been shown that when PEA15 is phosphorylated at Ser104 it blocks ERK binding in vitro and in vivo, whereas it promotes binding to the proapoptotic protein FADD when it is phosphorylated at Ser116, resulting in inhibition of apoptosis (Renganathan et al., 2005) . The role of the phosphorylation status of PEA15 in tumorigenicity needs further investigation.
In contrast to our findings here are observations that high levels of PEA15 (e.g., in MDA-MB-231 and BT20 cells) are implicated in tumorigenicity (Ramos et al., 2000) . One explanation for this apparent discrepancy could be that the 2.4-kb cDNA for PEA15 contains the entire sequence from the proto-oncogene MAT1, and deregulation of this MAT1 region may contribute to the apparent tumorigenicity of PEA15 (Estelles et al., 1996) . MAT1 is known to neoplastically transform NIH3T3 mouse fibroblasts and the mammary epithelial cell line TM3 (Bera et al., 1994) . Another study reported that the human homolog of MAT1 (hMAT1) was expressed in the human breast cancer cell lines MDA-MB-231, BT20, and T47D at levels 10 times higher than those in normal human mammary epithelial cells (Hwang et al., 1997) ; this difference in hMAT1 expression level may be partly responsible for the tumorigenicity of MDA-MB-231 and BT20 cells. Further, the phosphorylated PEA15 has resulted in increased proliferation of cells, which may be a reason for the tumorigenicity of these cells. Thus, investigations are needed to clarify the link between PEA15 expression level and tumorigenicity.
E1A alone cannot transform primary cell lines or established cell lines and therefore is not in itself a transforming oncogene; rather, transformation requires the presence of a second oncogene, activated ras (Land et al., 1983; Ruley, 1983; Byrd et al., 1988) . Also, cells treated with E1A in combination with Ha-RasV12 form colonies in soft agar, but they cannot form tumors in immunocompromised mice. However, the combination of E1A plus Ha-RasV12 plus MDM2 can, without activating telomerase, convert normal human fibroblasts to cancer cells that do form tumors in mice (Seger et al., 2002) . E1A has never been shown to induce E1A antitumor effect via PEA15 C Bartholomeusz et al tumorigenicity in human cells (Byrd et al., 1988; Frisch and Mymryk, 2002) ; rather, E1A reverses the transformed phenotype and suppresses the growth of many different types of tumors, including breast and ovarian cancer, melanoma, and head and neck cancer (Yu et al., 1993; Zhang et al., 1995; Mymryk, 1996; Deng et al., 1998; Yoo et al., 2001 ). In our hands, E1A upregulated PEA15 and mediated an E1A-dependent antitumor effect through the mitogen-activated protein kinase pathway. Another recent report showed that E1A blocked Ras-induced senescence in normal human fibroblast cells by preventing the cytoplasmic localization of ERK1/2 through suppression of PEA15 (Gaumont- Leclerc et al., 2004) . The difference in the PEA15 results, like the E1A results, may reflect our use of human cancer cells rather than normal human fibroblast cells. Reduction of PEA15 in normal human fibroblasts occurs in the presence of oncogenic ras. In our studies, we used the human ovarian cancer cell line OVCAR-3, which lacks a mutated ras (Gum et al., 1996) . Therefore, E1A in association with ras may contribute to the reduction in PEA15 levels in normal human fibroblasts, restoring the nuclear localization of ERK 1/2 and inhibiting ras-induced senescence. Even though adenoviral infection is widespread in humans, E1A sequences have never been found in human tumors. As noted in the previous paragraph, the adenovirus E1A is nononcogenic in human cells (Frisch, 2004) . Collectively, all of this information led the US Food and Drug Administration and Research Advisory Committee in 1995 to allow us to conduct clinical trials of E1A gene therapy for patients with cancer. Several phase I and phase II clinical trials of such therapy have been completed for breast, ovarian, and head and neck cancers (Hortobagyi et al., 2001; Yoo et al., 2001) , and no side effects related to tumor formation have been found. The protocol used in these trials involves a transient gene transduction system that only expresses E1A in target cells transiently; it does not integrate E1A sequences into the DNA of host cells, thereby reducing the potential to form tumors. We do recognize that E1A can transform human normal cells under certain conditions; however, type 5 E1A has not been shown to produce tumor in clinical settings. We acknowledge this concern and recommend that patients given E1A gene therapy undergo long-term, careful monitoring.
In summary, we found that the antitumor activity of E1A in ovarian cancer depends on PEA15. PEA15 itself has growth-inhibitory effects in some breast and ovarian cancer cells. These observations may have important implications for using PEA15 as a therapeutic gene in the treatment of ovarian and breast cancer. Additional studies are needed to clarify the mechanistic role of PEA15 in tumor suppression. We have already determined through screens for PEA15 expression that four of seven human ovarian cancer cell lines expressed low levels of PEA15 (data not shown). Our next studies of PEA15 involve screening tumor samples from participants in the phase I/II clinical trials of E1A gene therapy currently underway at the MD Anderson Cancer Center.
Materials and methods
Cell lines and culture conditions SKOV3.ip1 cells express high levels of HER2 (Yu et al., 1993) , whereas OVCAR-3 ovarian cancer cells (Xu et al., 1999) and MDA-MB-435 and MDA-MB-231 breast cancer cells express only basal levels of HER2 (Ueno et al., 1997) . SKOV3.ip1, MDA-MB-435, and MDA-MB-231 cells were grown in DMEM/F12 medium (GIBCO, Grand Island, NY), and OVCAR-3 cells were grown in RPMI 1640 (GIBCO) supplemented with 2 mM L-glutamine, 10% fetal bovine serum (FBS), and penicillin/streptomycin in a humidified incubator at 371C with 5% CO 2 .
Transfection conditions
For E1A transfections, two stably transfected cell lines, OVCAR-NP and OVCAR-E1A, were established by transfecting 10 mg of either a control vector (pSV 2 -neo) (BD Biosciences, Palo Alto, CA, USA) or pSV 2 expressing the adenovirus type 5 E1A gene (pAd.E1A-neo) into OVCAR-3 cells with 3b(N-(N 0 ,N 0 -dimethylaminoethane)-carbamoyl) cholesterol (DC-Chol), a cationic derivative of cholesterol, and dioleoylphosphatidylethanol-amine (DOPE) (Ueno et al., 2000) . Four OVCAR-E1A clones (OVCAR-E27, -E28, -E39, and -E43) were established. The -E27 and -E28 clones had similarly high expression of E1A relative to that of the -E39 and -E43 clones.
Other E1A transfections involved use of two adenoviral vectors: Ad.E1A( þ ), an adenovirus type 5-based vector containing E1A but lacking E1B and E3; and Ad.E1A(-), a control vector similar to Ad.E1A( þ ) but lacking E1A (Yan et al., 1991; Zhang et al., 1995) . Viability of the transfected OVCAR-3 cells was verified by trypan blue exclusion. Briefly, 3 Â 10 5 cells were plated on 35-mm tissue culture dishes and 24 h later infected with 10 MOI Ad.E1A(-) or Ad.E1A( þ ) in replicates of three. Cells were stained with 0.2% trypan blue at 24, 48, 96, or 120 h after infection, and living cells and dead cells were counted under a microscope.
The PEA15 transfectants were established as follows. Two human ovarian cancer cell lines (SKOV3.ip1, OVCAR-3) and two breast cancer cell lines (MDA-MB-231, MDA-MB-435) were seeded on 100-mm plates and transfected with 10 mg of either a vector containing HA-tagged PEA15 (Formstecher et al., 2001) or a control vector (pcDNA3) (Stratagene, La Jolla, CA, USA) by means of DC-Chol cationic liposomes. Both plasmids contain a neomycin-resistance gene. At 48 h after transfection, cells were trypsinized, diluted 1:5 or 1:10, plated on 100-mm plates, and grown in RPMI 1640 containing 200 mg/ml of G418 (OVCAR-3) or DMEM/F12 containing 1000 mg/ml of G418 (SKOV3.ip1). After 3 weeks, colonies were counted (after staining with 0.5% crystal violet in 20% ethanol) and individual neomycin-resistant colonies were cloned and expanded to mass culture. Three SKOV3.ip1-PEA15 clones (ip1-P1, -P2, -P3) were established and used for the experiments.
Western blot analysis Cells were washed three times with PBS and then lysed in lysis buffer (20 mM Na 2 PO 4 , pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% aprotinin, 1 mM phenylmethylsulfonyl fluoride, 100 mM NaF, and 2 mM Na 3 VO 4 ) as described previously (Ueno et al., 2000) . PEA15 was extracted with NP-40 lysis buffer as described previously (Hao et al., 2001) . The rabbit anti-PEA15 polyclonal antibody 4513 (used in a 1:1000 dilution) was provided by Mark H Ginsberg. Other primary antibodies used were ERK (in a 1:500 dilution) and pERK (in a 1:500 dilution) (both from Santa Cruz Biotechnology, Santa Cruz, CA, USA), actin (1:5000) (Sigma-Aldrich Chemical Co., Saint Louis, MO, USA), poly(ADP-ribose) polymerase (PARP) (1:1000) (BD Biosciences), a-tubulin (1:5000) (Sigma-Aldrich), and E1A (1:500) (BD Biosciences). The rabbit (1:8000) and mouse (1:5000) secondary antibodies were from Jackson ImmunoResearch (West Grove, PA, USA). The relative intensity of the immunoblots was quantified by the NIH Image program (available at http://rsb.info.nih.gov/ nih-image/Default.html), which provides the sum of the grayscale values of all pixels within selected regions of interest. Ratios were calculated for each cell line to compare density of the pERK protein in the cytoplasm and in the nucleus.
Immunofluorescence studies Cells were grown for 1 day on Labtek chamber slides at 20 000 cells/well, after which the medium was removed and the cells were washed three times with ice-cold PBS (5 min per wash) and fixed in 4% paraformaldehyde for 20 min at room temperature. After another three 5-min washes in ice-cold PBS, cells were permeabilized in 0.2% Triton-X in PBS for 10 min at room temperature, washed again in PBS, and blocked in 5% normal goat serum (DakoCytomation, Carpinteria, CA, USA) for 1 h at room temperature. Cells were then incubated overnight at room temperature with the following primary antibodies: polyclonal rabbit anti-PEA15 antibody at a 1:100 dilution (SynPep, Dublin, CA, USA) and monoclonal anti-mouse pERK (Santa Cruz Biotechnology) at 1:50. The next day, the cells were washed three times with PBS and incubated for 1 h with either goat anti-rabbit FITC secondary antibody (Biosource, Camarillo, CA, USA) at a 1:500 dilution or goat anti-mouse Texas Red secondary antibody (Molecular Probes, Eugene, OR, USA) at 1:500. Cells were visualized with either a confocal laser-scanning microscope (Olympus, Japan) or a Zeiss AxioPlan2 fluorescence microscope. The nuclei were stained with propidium iodide (for confocal microscopy) or 4 0 ,6-diamidino-2-phenylindole (DAPI) (for fluorescence microscopy) before mounting. The relative intensity of the fluorescence was quantified by using the NIH Image program. Briefly, confocal images are captured with a digital camera and imported into the program. The program then converts the images to gray-scale and binary images, allowing the computer to distinguish areas of immunoreactivity from background; the fluorescence intensity of both background and cytoplasmic areas is measured, and background is then eliminated through a standardized process. Then the cytoplasmic areas are selected on an image displayed on the computer monitor, the absolute fluorescence intensity in each cell is recorded, and the data are then imported into Microsoft Excel. After more than five cells were analysed, means of the intensity values are obtained for each group and compared. The percentage of cells with nuclear staining (pERK) was expressed as a percentage of the total number of cells. w 2 tests were used for statistical comparisons. A P-value of o0.05 was considered statistically significant.
Evaluation of anchorage-independent growth
To assess anchorage-independent growth, an indicator of in vivo tumorigenicity (Zhang et al., 1995) , we mixed cells at 371C with 0.5% agarose in complete medium and poured the mixture over a layer of 1% agarose in complete medium in sixwell plates. The top layer was allowed to gel at 41C for 15 min, and the plates were then incubated at 371C for 3 weeks. At 3 weeks, the plates were stained by adding p-iodonitrotetrazolium violet to each well and incubated at 371C for 24 h, after which the colonies were photographed with a Zeiss microscope and counted by using the software associated with the microscope.
Evaluation of DNA synthesis DNA synthesis was measured with a BrdU labeling and detection kit (Roche Diagnostics, Indianapolis, IN, USA) as follows. The parental cell line (OVCAR-3), the neomycin-pool control cells (OVCAR-NP), and two E1A transfectant clones (OVCAR-E27 and OVCAR-E28) were plated on a fourchamber slide in duplicate at 20 000 cells/well and incubated with BrdU labeling medium for 40 min at 371C. Percentages of BrdU-labeled cells were evaluated by fluorescence microscopy with a Zeiss microscope.
In another set of experiments, cells were transfected with small interfering (si) RNA constructs against PEA15 or a scrambled control sequence (described below) for 30 h, after which culture medium containing BrdU was added and the cells were incubated for an additional 20 h. Direct immunofluorescence staining was performed according to the manufacturer's protocol (Becton Dickinson, San Jose, CA, USA) and the samples were analysed on a BD FACScan flow cytometer.
siRNA transfection Cells (2 Â 10 5 cells per well) were seeded in six-well culture plates in RPMI medium supplemented with 10% FBS at 30-50% confluence. The next day, cells were transfected with siPEA15 (GGAAGACATCCCCAGCGAATT) or a scrambled siRNA duplex (siControl) (Dharmacon Inc., Lafayette, CO, USA) at a final siRNA concentration of 200 nM by using oligofectamine (Invitrogen, Palo Alto, CA, USA) and incubated for 4 h. Next, FBS was added to reach a final concentration of 20% FBS in the wells. Cells were fixed 24, 48, or 96 h later and subjected to immunofluorescence studies.
Nuclear/cytoplasmic fractionation OVCAR-NP and OVCAR-E27 cells were plated at 2 Â 10 5 cells/well in RPMI medium containing 10% FBS and incubated at 371C for 24 h, after which they were grown in medium containing 2% serum overnight and then stimulated with 20% serum for 30 min. Cells were pelleted and the nuclear and cytoplasmic fractions were separated with a nuclear/ cytosol fractionation kit according to the manufacturer's protocol (BioVision, Mountain View, CA, USA). Protein concentrations in the cytoplasmic and nuclear fractions were measured with a protein assay kit from Bio-Rad Laboratories (Hercules, CA, USA).
Elk-1 transcription assay
The PathDetect Elk-1 trans-reporting system (Stratagene, La Jolla, CA, USA) was used according to the manufacturer's protocol. Briefly, OVCAR-NP and OVCAR-E1A cells (2 Â 10 5 cells/well) were plated on 35-mm plates, and the next day the cells were cotransfected with pFA2-Elk-1, pFR-luciferase, and the internal transfection control vector pRL-TK (Promega Biosciences, San Luis Obispo, CA, USA). Cells were grown in medium containing 0.5% serum overnight and then stimulated with medium containing 20% serum for 30 min. Cells were then harvested and Elk-1 transcription was measured in terms of luciferase activity by using Promega's dual luciferase assay system according to the manufacturer's protocol. Elk-1-luciferase activity was normalized against the internal control luciferase activity of pRL-TK.
In another set of experiments, OVCAR-E1A cells (2 Â 10 5 cells/well) were transfected with siControl or siPEA15 constructs as described under 'siRNA transfection'. After 24 h, cells were cotransfected with pFA2-Elk-1, pFR-luciferase, and pRL-TK (Promega Biosciences), and, after another 24 h, cells were grown in medium containing 0.5% serum overnight and then stimulated with medium containing 20% serum for 30 min. Cells were then harvested and Elk-1 transcription was measured as described above.
